Comparative cardiovascular outcomes in type 2 diabetes patients taking dapagliflozin versus empagliflozin: a nationwide population-based cohort study
Main finding · Composite of HF-related events, MI, ischemic stroke and cardiovascular deathResult — go to the resultHazard ratio 0.93 95% CI 0.855–1.006Authors' conclusion
This large-scale nationwide population-based real-world cohort study revealed no significant difference in composite cardiovascular outcomes between new users of dapagliflozin and empagliflozin. However, dapagliflozin might be associated with lower risks of hospitalization or death due to HF and cardiovascular death than empagliflozin in Asian patients with type 2 diabetes mellitus.
Study context
- Population
- Patients with T2D, Korean National Health Insurance registry, May 2016–December 2018; mean age ≈56 years, 42% women; ≈40% with T2D as sole cardiovascular risk factornew users identified
- Participants
- 366,031 patients
- Exposure
- Dapagliflozin vs empagliflozin
- Dapagliflozinn = 72,752
- Empagliflozinn = 72,752reference
- Outcome
- Composite of:
- Heart failure (HF)-related events (hospitalization for HF and HF-related death)
- MI
- Ischemic stroke
- Cardiovascular death
Methodological detailsnationwide, active-comparator new-user design, 1:1 nearest-neighbor propensity score matching, real-world
- Nationwide
- Active-comparator new-user design
- 1:1 nearest-neighbor propensity score matching
- Real-world
Main finding
As reported in the abstract
Composite of:
- HF-related events
- MI
- Ischemic stroke
- Cardiovascular death
Hazard ratio
0.93
95% CI 0.855–1.006
Dapagliflozinvs Empagliflozin
HR 0.93 (95% CI 0.855–1.006)
Observational data: associations, not effects.
Secondary outcomes
| Outcome | HR (95% CI) | |
|---|---|---|
| HF-related events | 0.84 (0.714–0.989) | |
| Cardiovascular death | 0.76 (0.618–0.921) | |
| 0.512Hazard ratio (log scale) |
Other individual components of the primary outcome
- Risks of other secondary outcomes were similar
Original publication
Comparative cardiovascular outcomes in type 2 diabetes patients taking dapagliflozin versus empagliflozin: a nationwide population-based cohort study. Cardiovasc Diabetol. Published 26 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →